StonvexLoading…
StonvexStonvexStonvexCore line items from BBIO's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $502.08M | $221.90M | $9.30M | $77.65M |
Operating Income | $-523.41M | $-592.97M | $-607.37M | $-512.20M |
Net Income | $-732.94M | $-543.35M | $-653.25M | $-484.65M |
EPS (Diluted) | $-3.78 | $-2.88 | $-3.95 | $-3.26 |
Total Assets | $936.02M | $919.34M | $546.38M | $623.04M |
Total Liabilities | $3.01B | $2.38B | $1.89B | $1.87B |
Cash & Equivalents | $570.12M | $681.10M | $375.94M | $376.69M |
Free Cash Flow OCF − CapEx | $-447.01M | $-521.66M | $-529.03M | $-424.31M |
Shares Outstanding | 194.77M | 190.04M | 175.08M | 150.63M |